Table 2 Correlation between CDC20 expression and clinical features in 51 MCL patients
Clinical features | Cases, N | CDC20 expression | χ2 | P value | |
|---|---|---|---|---|---|
Low, n (%) | High, n (%) | ||||
Total | 51 | 21 (41.2) | 30 (58.8) | Â | Â |
Age | |||||
 <60 | 21 | 9 (42.9) | 12 (57.1) | 0.042 | 0.838 |
  ≥ 60 | 30 | 12 (40.0) | 18 (60.0) |  |  |
Gender | |||||
 Male | 39 | 15 (38.5) | 24 (61.5) | 0.140 | 0.708 |
 Female | 12 | 6 (50.0) | 6 (50.0) |  |  |
B symptoms | |||||
 Yes | 24 | 8 (33.3) | 16 (66.7) | 1.151 | 0.283 |
 No | 27 | 13 (48.1) | 14 (51.9) |  |  |
Pathological type | |||||
 Indolent | 9 | 5 (55.6) | 4 (44.4) | 0.351 | 0.553 |
 Aggressive | 42 | 16 (38.1) | 26 (61.9) |  |  |
ECOG | |||||
 <2 | 45 | 20 (44.4) | 25 (55.6) | 0.735 | 0.391 |
  ≥ 2 | 6 | 1 (16.7) | 5 (83.3) |  |  |
Ki-67 | |||||
 <30% | 19 | 12 (63.2) | 7 (36.8) | 6.041 | 0.014* |
  ≥ 30% | 32 | 9 (28.1) | 23 (71.9) |  |  |
WBC | |||||
 <10*10^9/L | 34 | 13 (38.2) | 21 (61.8) | 0.364 | 0.546 |
  ≥ 10*10^9/L | 17 | 8 (47.1) | 9 (52.9) |  |  |
β2-MG | |||||
 <3 mg/L | 21 | 11 (52.4) | 10 (47.6) | 1.850 | 0.174 |
  ≥ 3 mg/L | 30 | 10 (33.3) | 20 (66.7) |  |  |
LDH | |||||
 <240 IU/L | 30 | 17 (56.7) | 13 (43.3) | 7.217 | 0.007** |
  ≥ 240 IU/L | 21 | 4 (19.0) | 17 (81.0) |  |  |
Stage | |||||
 I-II | 11 | 8 (72.7) | 3 (27.3) | 4.223 | 0.040* |
 III-IV | 40 | 13 (32.5) | 27 (67.5) |  |  |
MIPI | |||||
 Low risk | 20 | 13 (65.0) | 7 (35.0) | 9.743 | 0.008** |
 Intermediate risk | 12 | 5 (41.7) | 7 (58.3) |  |  |
 High risk | 19 | 3 (15.8) | 16 (84.2) |  |  |
Involved lymph node areas | |||||
 <3 | 16 | 10 (62.5) | 6 (37.5) | 4.377 | 0.036* |
  ≥ 3 | 35 | 11 (31.4) | 24 (68.6) |  |  |
BM involvement | |||||
 Yes | 41 | 13 (31.7) | 28 (68.3) | 5.875 | 0.015* |
 No | 10 | 8 (80.0) | 2 (20.0) |  |  |
Treatment response | |||||
 CR/PR | 31 | 18 (58.1) | 13(41.9) | 9.308 | 0.002** |
 SD/PD | 20 | 3 (15.0) | 17 (85.0) |  |  |